Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 Variant Vaccines in Healthy Individuals
NCT05997290Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Aug 2023; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05997290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997290.